Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Short term Debt (2016 - 2021)

ImmunityBio (IBRX) has disclosed Short term Debt for 8 consecutive years, with $8.7 million as the latest value for Q3 2021.

  • On a quarterly basis, Short term Debt rose 541.37% to $8.7 million in Q3 2021 year-over-year; TTM through Sep 2021 was $8.7 million, a 541.37% increase, with the full-year FY2020 number at $14.8 million, up 2953.09% from a year prior.
  • Short term Debt was $8.7 million for Q3 2021 at ImmunityBio, down from $16.7 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $17.8 million in Q1 2021 to a low of $486000.0 in Q4 2019.
  • A 5-year average of $4.5 million and a median of $2.1 million in 2017 define the central range for Short term Debt.
  • Peak YoY movement for Short term Debt: tumbled 71.34% in 2019, then soared 2953.09% in 2020.
  • ImmunityBio's Short term Debt stood at $2.4 million in 2017, then dropped by 28.23% to $1.7 million in 2018, then crashed by 71.34% to $486000.0 in 2019, then skyrocketed by 2953.09% to $14.8 million in 2020, then crashed by 41.39% to $8.7 million in 2021.
  • Per Business Quant, the three most recent readings for IBRX's Short term Debt are $8.7 million (Q3 2021), $16.7 million (Q2 2021), and $17.8 million (Q1 2021).